Free Trial

LeMaitre Vascular Q2 2023 Earnings Report

LeMaitre Vascular logo
$91.62 +0.69 (+0.76%)
(As of 01:34 PM ET)

LeMaitre Vascular EPS Results

Actual EPS
$0.37
Consensus EPS
$0.32
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

LeMaitre Vascular Revenue Results

Actual Revenue
$50.12 million
Expected Revenue
$48.29 million
Beat/Miss
Beat by +$1.83 million
YoY Revenue Growth
N/A

LeMaitre Vascular Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

The #1 Coin for November 2024 (Ad)

‘Gift’ Yourself a Potential 10,000% Win! #1 Crypto to Buy Before 2025 REVEALED!

Click here to get all the details on this crypto coin now.

LeMaitre Vascular Earnings Headlines

LeMaitre Vascular Prices $150M Convertible Notes Offering
The #1 Coin for November 2024
‘Gift’ Yourself a Potential 10,000% Win! #1 Crypto to Buy Before 2025 REVEALED!
LeMaitre Vascular Prices $150 Million Convertible Senior Notes
LeMaitre Vascular To Offer $150 Mln Of Senior Notes; Pre-Market Stock Down
See More LeMaitre Vascular Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LeMaitre Vascular? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LeMaitre Vascular and other key companies, straight to your email.

About LeMaitre Vascular

LeMaitre Vascular (NASDAQ:LMAT) develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

View LeMaitre Vascular Profile

More Earnings Resources from MarketBeat

Upcoming Earnings